Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Favipiravir for COVID-19: real-time meta analysis of 43 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19favipiravir.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Ruzhentsova (RCT) 39% 0.61 [0.43-0.88] no recov. 112 (n) 56 (n) Ruzhentsova (RCT) 22% 0.78 [0.92-1.79] viral+ 112 (n) 56 (n) Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Udwadia (RCT) 29% 0.71 [0.46-1.10] viral time 75 (n) 75 (n) Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Holubar (DB RCT) 30% 0.70 [0.23-2.12] ER visit 5/75 7/74 Holubar (DB RCT) -19% 1.19 [0.78-1.85] no recov. 65 (n) 70 (n) Holubar (DB RCT) -32% 1.32 [0.83-2.08] viral+ 59 (n) 57 (n) Alattar (PSM) 33% 0.67 [0.28-1.61] death 8/387 12/387 Alattar (PSM) -2% 1.02 [0.90-1.16] no recov. 26/387 28/387 Alattar (PSM) -6% 1.06 [0.99-1.14] recov. time 387 (n) 387 (n) Alattar (PSM) 44% 0.56 [0.44-0.71] viral+ 78/387 139/387 Bosaeed (DB RCT) -619% 7.19 [0.38-138] ICU 3/112 0/119 Bosaeed (DB RCT) -219% 3.19 [0.66-15.5] hosp. 6/112 2/119 Bosaeed (DB RCT) -12% 1.12 [0.80-1.56] no recov. 112 (n) 119 (n) Bosaeed (DB RCT) -15% 1.15 [0.75-1.75] viral+ 112 (n) 119 (n) Lowe (DB RCT) -196% 2.96 [0.12-71.1] ICU 1/54 0/52 Lowe (DB RCT) -196% 2.96 [0.12-71.1] hosp. 1/54 0/52 Lowe (DB RCT) 28% 0.72 [0.44-0.98] viral+ 29/54 38/52 Adhikari (RCT) -40% 1.40 [0.57-3.44] no improv. 10/38 6/32 Adhikari (RCT) -36% 1.36 [0.52-3.59] no improv. 8/27 5/23 Adhikari (RCT) -64% 1.64 [0.18-15.3] no improv. 2/11 1/9 Tsuzuki 13% 0.87 [0.52-1.46] death 2,532 (n) 5,122 (n) Tsuzuki -2% 1.02 [0.65-1.60] ventilation 2,532 (n) 5,122 (n) Tsuzuki 18% 0.82 [0.66-1.04] progression 2,532 (n) 5,122 (n) Qadir 97% 0.03 [0.00-0.47] death 0/125 17/125 Qadir 60% 0.40 [0.23-0.71] hosp. 14/125 35/125 Qadir 97% 0.03 [0.00-0.47] no recov. 0/125 17/125 Qadir 71% 0.29 [0.17-0.50] no recov. 14/125 48/125 Qadir 79% 0.21 [0.13-0.36] no recov. 14/125 66/125 Qadir 71% 0.29 [0.22-0.40] no recov. 32/125 109/125 Qadir 58% 0.42 [0.25-0.70] recov. time 125 (n) 125 (n) Sirijatuphat (RCT) 64% 0.36 [0.20-0.64] improv. 62 (n) 31 (n) Sirijatuphat (RCT) 90% 0.10 [0.03-0.39] improv. 62 (n) 31 (n) Sirijatuphat (RCT) 43% 0.57 [0.23-1.43] progression 8/62 7/31 Sirijatuphat (RCT) -4% 1.04 [0.63-1.72] viral+ 62 (n) 31 (n) McMahon (RCT) -1% 1.01 [0.34-3.03] oxygen 6/99 6/100 McMahon (RCT) -56% 1.56 [0.71-3.43] hosp. 14/99 9/99 Cai 69% 0.31 [0.10-0.96] pneumonia 35 (n) 45 (n) Cai 71% 0.29 [0.10-0.86] viral+ 35 (n) 45 (n) Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Ivashchenko (RCT) 62% 0.38 [0.09-1.52] viral+ 3/40 4/20 Ivashchenko (RCT) -67% 1.67 [0.52-5.39] no disch. 10/40 3/20 Ivashchenko (RCT) -300% 4.00 [0.20-79.6] hosp. 2/40 0/20 Lou (RCT) -422% 5.22 [0.28-96.2] ICU 2/9 0/10 Lou (RCT) -422% 5.22 [0.28-96.2] viral+ 2/9 0/10 Lou (RCT) -11% 1.11 [0.47-2.60] viral+ 5/9 5/10 Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Pushkar (RCT) 33% 0.67 [0.54-0.82] recov. time 100 (n) 100 (n) Pushkar (RCT) 45% 0.55 [0.42-0.72] no recov. 40/100 73/100 Pushkar (RCT) 20% 0.80 [0.64-1.00] recov. time 100 (n) 100 (n) Pushkar (RCT) 70% 0.30 [0.16-0.58] no disch. 10/100 33/100 Pushkar (RCT) 27% 0.73 [0.63-0.86] no recov. 66/100 90/100 Pushkar (RCT) 33% 0.67 [0.50-0.89] pneumonia 40/100 60/100 Pushkar (RCT) 90% 0.10 [0.02-0.40] viral+ 2/100 21/100 Khamis (RCT) 15% 0.85 [0.28-2.59] death 5/44 6/45 OT​1 CT​2 Khamis (RCT) -2% 1.02 [0.42-2.48] ICU 8/44 8/45 OT​1 CT​2 Khamis (RCT) -10% 1.10 [0.60-1.99] no recov. 15/44 14/45 OT​1 CT​2 Solaymani.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Solaymani.. (RCT) -53% 1.53 [0.86-2.71] ventilation 27/190 17/183 OT​1 Solaymani.. (RCT) -19% 1.19 [0.73-1.94] ICU 31/190 25/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Zhao (RCT) 52% 0.48 [0.25-0.91] viral time 36 (n) 19 (n) Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Alamer -56% 1.56 [0.73-3.36] death 12/233 21/223 Alamer 90% 0.10 [0.04-0.29] ventilation 4/218 27/165 Alamer 49% 0.51 [0.41-0.64] no disch. 221 (n) 201 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Almoosa -90% 1.90 [1.11-3.26] ICU 110 (n) 116 (n) Almoosa -11% 1.11 [0.96-1.29] recov. time 110 (n) 116 (n) Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Shinkai (SB RCT) 59% 0.41 [0.18-0.93] imp. time 47 (n) 13 (n) Assiri (ICU) -79% 1.79 [0.33-8.02] death 11/67 3/51 ICU patients Kulzhanova 88% 0.12 [0.04-0.37] no improv. 3/40 25/40 Kulzhanova 89% 0.11 [0.01-2.00] no improv. 0/40 4/40 Kulzhanova 50% 0.50 [0.21-1.20] viral+ 6/40 12/40 Chen (RCT) -3% 1.03 [0.15-7.22] ICU 2/116 2/120 OT​1 Chen (RCT) 74% 0.26 [0.03-2.28] resp. failure 1/116 4/120 OT​1 Chen (RCT) 20% 0.80 [0.48-1.34] oxygen 21/116 27/120 OT​1 Chen (RCT) 70% 0.30 [0.10-0.87] dyspnea 4/116 14/120 OT​1 Chen (RCT) 10% 0.90 [0.45-1.80] dyspnea 13/116 15/120 OT​1 Chen (RCT) 20% 0.80 [0.60-1.08] no recov. 45/116 58/120 OT​1 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Tabarsi (RCT) 30% 0.70 [0.17-2.88] death 3/32 4/30 OT​1 Tabarsi (RCT) 41% 0.59 [0.22-1.59] ICU 5/32 8/30 OT​1 Tabarsi (RCT) 6% 0.94 [0.72-1.23] CT imp. 24/32 24/30 OT​1 Tabarsi (RCT) 25% 0.75 [0.58-0.97] hosp. time 32 (n) 30 (n) OT​1 Atipornwa.. (RCT) 23% 0.77 [0.35-1.67] death 10/100 13/100 OT​1 CT​2 Atipornwa.. (RCT) 60% 0.40 [0.20-0.79] progression 10/100 25/100 OT​1 CT​2 Atipornwa.. (RCT) 9% 0.91 [0.73-1.14] viral time 50 (n) 50 (n) OT​1 CT​2 Atipornwa.. (RCT) 9% 0.91 [0.75-1.10] viral time 50 (n) 50 (n) OT​1 CT​2 Damayanti 54% 0.46 [0.22-0.92] no recov. 96 (n) 96 (n) Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Shenoy (DB RCT) -33% 1.33 [0.67-2.66] ventilation 17/175 13/178 Shenoy (DB RCT) -2% 1.02 [0.57-1.82] ICU 20/175 20/178 Shenoy (DB RCT) -1% 1.01 [0.78-1.30] no recov. 157 (n) 158 (n) Shenoy (DB RCT) 6% 0.94 [0.75-1.18] no recov. 175 (n) 178 (n) Shenoy (DB RCT) 17% 0.83 [0.58-1.18] no recov. 157 (n) 158 (n) Shenoy (DB RCT) 32% 0.68 [0.50-0.93] no recov. 175 (n) 178 (n) Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Chuah (RCT) -20% 1.20 [0.36-3.97] ventilation 6/250 5/250 Chuah (RCT) -9% 1.09 [0.49-2.31] ICU 13/250 12/250 Finberg (RCT) -200% 3.00 [0.13-70.3] death 1/25 0/25 Finberg (RCT) -200% 3.00 [0.13-70.3] ventilation 1/25 0/25 Finberg (RCT) 58% 0.42 [0.16-1.10] no recov. 25 (n) 25 (n) Finberg (RCT) -46% 1.46 [0.45-4.81] no recov. 25 (n) 25 (n) Finberg (RCT) 47% 0.53 [0.29-0.98] viral time 25 (n) 25 (n) Al Mutair (ICU) 7% 0.93 [0.77-1.12] death 119/269 128/269 ICU patients OT​1 Al Mutair (ICU) -9% 1.09 [0.82-1.43] ARDS 76/269 70/269 ICU patients OT​1 Al Mutair (ICU) -34% 1.34 [1.13-1.59] ICU 269 (n) 269 (n) ICU patients OT​1 Al Mutair (ICU) -37% 1.37 [1.14-1.64] hosp. time 269 (n) 269 (n) ICU patients OT​1 Kurniyanto 48% 0.52 [0.22-1.25] death 10/325 9/152 Cilli 38% 0.62 [0.24-1.63] death 5/23 8/23 Yulia 85% 0.15 [0.02-1.02] death n/a n/a Uyaroğlu (PSM) 67% 0.33 [0.01-7.96] death 0/42 1/42 OT​1 Uyaroğlu (PSM) -200% 3.00 [0.13-71.6] ICU 1/42 0/42 OT​1 Uyaroğlu (PSM) -11% 1.11 [0.24-5.08] hosp. time 42 (n) 42 (n) OT​1 AlQahtani (RCT) -196% 2.96 [0.12-71.1] death 1/54 0/52 AlQahtani (RCT) 76% 0.24 [0.03-2.08] ICU 1/54 4/52 AlQahtani (RCT) -42% 1.42 [0.50-4.04] no recov. 8/53 5/47 AlQahtani (RCT) 43% 0.57 [0.27-1.21] viral+ 8/40 14/40 Shinada 7% 0.93 [0.45-1.89] hosp. 17 (n) 17 (n) Shinada 55% 0.45 [0.21-0.96] viral+ 17 (n) 17 (n) Hassaniazad (RCT) 68% 0.32 [0.07-1.48] death 2/32 6/31 OT​1 Hassaniazad (RCT) 35% 0.65 [0.20-2.07] ICU 4/32 6/31 OT​1 Hassaniazad (RCT) 25% 0.75 [0.51-1.10] hosp. time 32 (n) 31 (n) OT​1 Hassaniazad (RCT) 18% 0.82 [0.62-1.08] viral+ 22/32 26/31 OT​1 Hafez -3% 1.03 [0.68-1.56] viral+ 59 (n) 1,446 (n) CT​2 Hafez 59% 0.41 [0.15-1.15] viral+ 4 (n) 1,446 (n) CT​2 Rahman (DB RCT) 89% 0.11 [0.01-0.75] no improv. 1/19 8/16 Rahman (DB RCT) 65% 0.35 [0.16-0.78] no improv. 5/19 12/16 Rahman (DB RCT) 47% 0.53 [0.34-0.81] no improv. 10/19 16/16 Rahman (DB RCT) 92% 0.08 [0.01-0.59] viral+ 1/25 12/25 Rahman (DB RCT) 62% 0.38 [0.18-0.80] viral+ 6/25 16/25 Rahman (DB RCT) 48% 0.52 [0.36-0.76] viral+ 13/25 25/25 favipiravir COVID-19 outcomes c19favipiravir.com Jun 2022 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors favipiravir Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit